EPHA2 and nasopharyngeal carcinoma: Additionally, research has found that major facilitator superfamily domain containing 4 A (MFSD4A) can recruit RNF149 to degrade EPH receptor A2 (EPHA2), thereby inhibiting its downstream PI3K-AKT-ERK1/2 signaling pathway and epithelial-mesenchymal transition, thus inhibiting the proliferation and metastasis of nasopharyngeal carcinoma, providing new ideas and opportunities for targeted therapy of nasopharyngeal carcinoma [28].